Skip to: Content | Navigation | Sub Navigation

Overview

Photodisinfection is a topical, non-antibiotic approach that destroys a broad range of microbes and their virulence factors. Ondine is the global leader in photodisinfection and photodynamic solutions, having modified the platform technology for use in a variety of different indications.

How photodisinfection Works

  1. The photosensitizing solution is applied to the treatment site where it preferentially binds to the targeted microbes. The photosensitizer molecules are inactive at this stage.
  2. A laser of a specific wavelength and intensity illuminates the treatment site. The wavelength is carefully chosen to maximize absorption of light energy by the photosensitizer.
  3. A photocatalytic reaction occurs. This results in the destruction of the targeted microbes and their virulence factors, without damaging host cells. This reaction involves the formation of short-lived, highly reactive free-radical oxygen species.
  4. When the light is removed the photocatalytic reaction ceases.

Photodisinfection causes a physical disruption of the microbial cell membrane through oxidative reactions, resulting in immediate cell lysis. The process has also been shown to eliminate a multitude of virulence factors, lending to a clinically observable anti-inflammatory effect.

Unlike antibiotics, which require hours to days to exert their effect, photodisinfection works instantaneously, destroying microbes upon light activation. In addition, the surface-active nature of the photodisinfection process avoids direct exposure to the bacterial genome. These features make it highly unlikely that microorganisms will develop resistance to photodisinfection, thus positioning the technology as an attractive alternative to antibiotic treatment for non-systemic infections.

The United States Food and Drug Administration and other regulating bodies have approved photodynamic therapies (using different photosensitizing drugs developed by others) for a number of proliferative diseases, including a variety of cancers as well as age-related macular degeneration, the primary cause of blindness in older adults. Periowave™ is currently under review for Premarket Approval by the US FDA.